<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Animal studies show that increasing large bowel <z:chebi fb="0" ids="17968">butyrate</z:chebi> concentration through ingestion of butyrylated or resistant starches opposes carcinogen-induced <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, which is consistent with population data linking greater fiber consumption with lowered <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) risk </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="17968">Butyrate</z:chebi> has been shown to regulate the apoptotic response to DNA damage </plain></SENT>
<SENT sid="2" pm="."><plain>This study examined the impact of increasing large bowel <z:chebi fb="0" ids="17968">butyrate</z:chebi> concentration by dietary butyrylated <z:chebi fb="99" ids="28017">starch</z:chebi> on the colonic epithelium of rats treated with the genotoxic carcinogen azoxymethane (AOM) </plain></SENT>
<SENT sid="3" pm="."><plain>Four groups of 10 male rats were fed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIN</z:e>-93G based-diets containing either low <z:chebi fb="0" ids="28102">amylose</z:chebi> maize <z:chebi fb="99" ids="28017">starch</z:chebi> (LAMS), LAMS with 3% tributyrin, 10% high <z:chebi fb="0" ids="28102">amylose</z:chebi> maize <z:chebi fb="99" ids="28017">starch</z:chebi> (HAMS) or 10% butyrylated HAMS (HAMSB) </plain></SENT>
<SENT sid="4" pm="."><plain>HAMS and HAMSB starches were cooked by heating in water </plain></SENT>
<SENT sid="5" pm="."><plain>After 4 weeks, rats were injected once with AOM and killed 6 h later </plain></SENT>
<SENT sid="6" pm="."><plain>Rates of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and proliferation were measured in colonic epithelium </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="26666">Short-chain fatty acid</z:chebi> concentrations in large bowel digesta and hepatic portal venous plasma were higher in HAMSB than <z:hpo ids='HP_0000001'>all</z:hpo> other groups </plain></SENT>
<SENT sid="8" pm="."><plain>Apoptotic rates in the distal colon were increased by HAMSB and correlated with <z:chebi fb="2" ids="8069">luminal</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> concentrations but cellular proliferation rates were unaffected by diet </plain></SENT>
<SENT sid="9" pm="."><plain>The increase in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was most marked in the base and proliferative zone of the crypt </plain></SENT>
<SENT sid="10" pm="."><plain>Regulation of <z:chebi fb="2" ids="8069">luminal</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> using HAMSB increases the rates of apoptotic deletion of DNA-damaged colonocytes </plain></SENT>
<SENT sid="11" pm="."><plain>We propose this pro-apoptotic function of <z:chebi fb="0" ids="17968">butyrate</z:chebi> plays a major role reducing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> formation in the AOM-treated rat and that these data support a potential protective role of <z:chebi fb="0" ids="17968">butyrate</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>